PowerShares DWA Healthcare Momentum ETF
Most Recent
MEDNAX Revenue and Income Rose After 3Q15 Results
MEDNAX’s YTD price movement was a mix of rises and falls in 2015. After the earnings report, MEDNAX fell 3.4% to close at $71.3 per share as of October 29, 2015.
What Are Sage Therapeutics’ Receptor-Based Products?
Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders.
Cooper Companies Reported Mixed 2Q15 Results
Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.
Ignyta and Its Key Risks in 2018
In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.
Naglazyme: One of the Costliest Drugs in the United States
The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.
